Top

About this Webinar

Thursday, October 1; 2:00 – 3:00 PM EDT

Biodesix® Inc., a diagnostic company with expertise in developing novel tests for lung diseases, has joined the fight against COVID-19. Through their partnership with Bio-Rad Laboratories, Biodesix offers two highly accurate EUA-FDA authorized tests for COVID-19. In addition to offering testing, Biodesix has developed the Biodesix WorkSafe™ Program.

In this webinar, learn about this effective testing solution designed to assist organizations in their goals of slowing and preventing the spread of COVID-19 while safely resuming business operations.

  • Hear the latest trends in COVID testing
  • Gain insight into a comprehensive testing program for employers
    • Learn about the customizable WorkSafe program
    • Discuss COVID-19 testing options
  • Deploy a daily screening tool to identify at-risk individuals

This webinar is co-hosted by World Congress and Validation Institute.

Speakers

Bobbi Coffin
Chief Growth Officer
Biodesix
View Bio

Mohannad Kusti, MD, MPH
Regional Medical Director, PIVOT Onsite Innovations;
Former Chief Medical Officer, United States Steel Corporation
View Bio

Hestia Mellert, PhD
Director of Development
Biodesix
View Bio

Sponsored By:

Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence.

Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy consisting of the Nodify XL2™ test and the Nodify CDT™ test evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, please visit www.biodesix.com.